| Cell line name |
L2-KS |
|---|
| Accession |
CVCL_E7ZU |
|---|
| Resource Identification Initiative |
To cite this cell line use: L2-KS (RRID:CVCL_E7ZU) |
|---|
| Comments |
Monoclonal antibody isotype: IgG1.
Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. |
|---|
| Species of origin |
Mus musculus (Mouse)
(NCBI Taxonomy: 10090) |
|---|
| Hierarchy |
Parent: CVCL_D145 (HL-1 Friendly Myeloma-653) |
|---|
| Category |
Hybridoma |
|---|
| Publications | PubMed=2784353; DOI=10.1007/BF00204985; PMCID=PMC11038250
James J. Starling, Ronald S. Maciak, N. Ann Hinson, Cynthia Lynn Nichols, Stephen L. Briggs, Bennett Coleman Laguzza;
In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.
Cancer Immunol. Immunother. 28:171-178(1989) PubMed=2344798; DOI=10.1002/cyto.990110408
Philip Marder, Ronald S. Maciak, Rebecca L. Fouts, Robert S. Baker, James J. Starling;
Selective cloning of hybridoma cells for enhanced immunoglobulin production using flow cytometric cell sorting and automated laser nephelometry.
Cytometry 11:498-505(1990) Patent=US5264341
Ronald S. Maciak, Philip Marder;
Selective cloning for high monoclonal antibody secreting hybridoma.
Patent number US5264341, 23-Nov-1993 |
|---|
| Entry history |
|---|
| Entry creation | 10-Apr-2025 |
|---|
| Last entry update | 10-Apr-2025 |
|---|
| Version number | 1 |
|---|
